AYTU BIOPHARMA, INC

For the period ended Dec 31, 2025. Filed Feb 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 3, 2026

AYTU$1.81+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Total
Common Stock · Paid-in · Accumulated · Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balances, June 30, 2025	8,976,913	$1	$352,500	$(333,535)	$18,966
Stock-based compensation expense	—	—	114	—	114
Issuance of common stock from exercise of warrants	935,000	—	2,126	—	2,126
Net income	—	—	—	1,965	1,965
Balances, September 30, 2025	9,911,913	1	354,740	(331,570)	23,171
Stock-based compensation expense	271,295	—	283	—	283
Issuance of common stock from exercise of warrants	550,000	—	1,331	—	1,331
Net loss	—	—	—	(10,584)	(10,584)
Balances, December 31, 2025	10,733,208	$1	$356,354	$(342,154)	$14,201

Additional · Total
Common Stock · Paid-in · Accumulated · Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balances, June 30, 2024	5,972,638	$1	$347,688	$(319,973)	$27,716
Stock-based compensation expense	564	—	173	—	173
Issuance of common stock from exercise of warrants	176,000	—	463	—	463
Net income	—	—	—	1,474	1,474
Balances, September 30, 2024	6,149,202	1	348,324	(318,499)	29,826
Stock-based compensation expense	20,479	—	151	—	151
Net income	—	—	—	788	788
Balances, December 31, 2024	6,169,681	$1	$348,475	$(317,711)	$30,765

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.